MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ChIP-seq]
Ontology highlight
ABSTRACT: MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ChIP-seq]
PROVIDER: PRJNA1130939 | ENA |
REPOSITORIES: ENA
ACCESS DATA